Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [CNBC]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: CNBC
Gilead Sciences said on Monday it ?will buy cancer therapy partner Arcellx for an implied equity ?value of $7.8 ?billion, expanding ?their cell therapy development collaboration that started in 2022. Shares of Arcellx climbed 77.8% to $113.99 while ?Gilead fell ?about 1% in premarket ?trading. Gilead will pay $115 per share in cash at the deal's closing, which is at a premium of 79% ?to the stock's last close. Kite Pharma, a unit of Gilead Sciences, ?was partnering with Arcellx to jointly develop and sell anito-cel, an experimental CAR-T therapy for multiple myeloma, a type ?of blood cancer. CAR-T cell therapy is a cancer treatment ?that uses a patient's own ?genetically modified immune cells to find and kill cancer cells. The U.S. Food and Drug Administration is ?currently reviewing the therapy, with a decision expected ?by December 23 this year. Upon FDA ?approval of anito-cel, the proposed transaction is expected to be accretive to earnings ?per share in ?2028 and ther
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences to Present at Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences to Present at Upcoming Investor ConferencesBusiness Wire
- Gilead Sciences (NASDAQ:GILD) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $170.00 price target on the stock.MarketBeat
- Gilead Sciences to Acquire Arcellx in $7.8 Billion Deal [Yahoo! Finance]Yahoo! Finance
- Gilead to acquire cancer therapy developer Arcellx for up to $7.8 billion [Yahoo! Finance Canada]Yahoo! Finance Canada
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 2/23/26 - Form 8-K
- 2/18/26 - Form 4
- 2/18/26 - Form 4
- GILD's page on the SEC website